Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan;34(1):e14433.
doi: 10.1111/dth.14433. Epub 2020 Oct 28.

Clinical context for cancer risk of immunosuppressive agents used in dermatology

Timothy Tyler Daugherty  1 , Robert Andrew Swerlick  2
Affiliations
Review

Clinical context for cancer risk of immunosuppressive agents used in dermatology

Timothy Tyler Daugherty et al. Dermatol Ther. 2021 Jan.

Abstract

Dermatologic care of inflammatory skin conditions has been transformed over recent decades through the use of small molecules disease-modifying anti-rheumatic drugs and targeted biologic therapies. Alongside the tremendous benefit of these agents, concerns remain regarding possible side effects, particularly cancer risk. To improve guidance and counseling of patients with skin diseases who are considering treatment with such agents, this article reviews available information on the risk of malignancies in patients treated with these agents. When possible, this article adds clinical context to risk through a number needed to harm that estimates the number of patients a provider would need to treat with a given agent in 1 year to cause a single adverse outcome over time.

Keywords: absolute risk; cancer; cancer risk; immunosuppression; malignancy; relative risk; skin cancer.

PubMed Disclaimer

References

REFERENCES

    1. Wilton KM, Matteson EL. Malignancy incidence, management, and prevention in patients with rheumatoid arthritis. Rheumatol Ther. 2017;4(2):333-347. https://doi.org/10.1007/s40744-017-0064-4.
    1. Axelrad JE, Lichtiger S, Yajnik V. Inflammatory bowel disease and cancer: the role of inflammation, immunosuppression, and cancer treatment. World J Gastroenterol. 2016;22(20):4794. https://doi.org/10.3748/wjg.v22.i20.4794.
    1. Legendre L, Barnetche T, Mazereeuw-Hautier J, Meyer N, Murrell D, Paul C. Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: a systematic review and meta-analysis. J Am Acad Dermatol. 2015;72(6):992-1002. https://doi.org/10.1016/j.jaad.2015.02.1116.
    1. Trafford AM, Parisi R, Kontopantelis E, Griffiths CEM, Ashcroft DM. Association of psoriasis with the risk of developing or dying of cancer: a systematic review and meta-analysis. JAMA Dermatol. 2019;155(12):1390. https://doi.org/10.1001/jamadermatol.2019.3056.
    1. Pouplard C, Brenaut E, Horreau C, et al. Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies. J Eur Acad Dermatol Venereol. 2013;27(Suppl 3):36-46. https://doi.org/10.1111/jdv.12165.

Substances

LinkOut - more resources